方法：以2008-06/2014-12收治的70例70眼麻痹性斜视患者为治疗组，以2000-10/2008-01收治的70例70眼麻痹性斜视患者为对照组。对照组接受常规治疗； 治疗组在对照组的基础上增加复方樟柳碱颞浅动脉旁皮下注射。治疗共进行两个疗程，总计28d，通过观察两组患者恢复状况及测定治疗前后两组患者MDA和SOD含量，评估复方樟柳碱对麻痹性斜视患者的临床疗效及对MDA和SOD的影响。

结果：治疗组中治愈54例54眼(77%)，好转14例14眼(20%)，无效2例2眼(3%)，总有效率97%； 对照组中治愈32例32眼(46%)，好转21例21眼(30%)，无效17例17眼(24%)，总有效率为76%，治疗组治愈率及总有效率显著高于对照组，差异有统计学意义(P<0.05)。治疗前，两组SOD及MDA水平无明显差异； 治疗后，两组患者血清SOD水平均升高，MDA水平均降低，但治疗组SOD升高及MDA降低水平显著优于对照组，差异有统计学意义(P<0.05)。

结论：复方樟柳碱对于麻痹性斜视患者具有良好的临床疗效，良好疗效可能与其较显著提高患者血清SOD含量、降低MDA含量有关。

METHODS: Seventy cases diagnosed with paralytic strabismus from Jun. 2008 to Dec. 2014 were selected as treatment group; another 70 cases with paralytic strabismus from Oct. 2000 to Jan. 2008 were chosen as control group. The control group was given with conventional therapy, and treatment group was additionally injected with compound anisodine subcutaneously on the basis of the control group. Treatment lasted for two courses about 28days. The effect of compound anisodine on patients with paralytic strabismus was evaluated and the serum level of MDA and SOD was also measured before and after treatment.

RESULTS: In treatment group, 54 cases were cured(77%), 14 cases improved(20%)and 2 cases had no response(3%)and total efficiency reached to 97%. In control group, 32 cases were cured(46%), 21 cases improved(30%)and 17 cases had no response(24%)and total efficiency was 76%. The cure rate and total efficiency of treatment group were significantly higher than that of control group(P<0.05). Before treatment, the level of SOD and MDA was equal in two groups. After treatment, increased SOD level and decreased MDA level was observed in both groups. However, compound anisodine were significantly increased SOD level and reduced MDA level when compared with conventional therapy(P<0.05).

CONCLUSION: The compound anisodine shows the beneficial effect on patients with paralytic strabismus. Compound anisodine may exert the effect via increasing SOD and reducing MDA.